Briapro therapeutics corp. announces availability of annual general meeting materials and alternative voting procedures

Vancouver, british columbia, dec. 17, 2024 (globe newswire) -- briapro therapeutics corp. (“briapro” or the “company”), a pre-clinical stage immunotherapy company developing binding agents and proteins with the intention to boost the ability of the body's own cancer-fighting cells to destroy cancerous tumors, announces that the company will be relying on, and has satisfied all of the conditions to rely on, csa coordinated blanket order 51-931 for exemption from the requirements to send proxy-related materials (the “meeting materials”) for its upcoming annual general meeting (the “meeting”) to be held on thursday, january 23, 2025, at suite 3400, one first canadian place, toronto, on, m5x 1a4. at 10:30 a.m. (est) due to the suspension of mail service in canada from the nationwide strike of the canadian union of postal workers that commenced on november 15, 2024. the meeting materials have been posted under the company's profile on sedar+ at www.sedarplus.ca (“sedar+”) and on the company's website at https://investors.briacell.com/briapro.
GM Ratings Summary
GM Quant Ranking